The Stem Cell Transplant Daily
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Teclistamab is effective in real-world patients with R/RMM, including those with prior anti-BCMA therapy exposure, albeit with slightly poorer progression-
Key Points. Multiple myeloma patients previously treated with T-cell redirection therapy have significantly low risk of developing CRS with teclistamabPati
Storytelling computers will change the course of human history, says the historian and philosopher
How a psychologist transformed economics
Blood Cancer Journal – Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Belantamab mafodotin (belantamab) is a first-in-class anti-BCMA antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for…
Key Points. Despite the high initial rates of response to anti-BCMA CAR-T cell therapy in myeloma, those responses are frequently short-lived.Exhausted CD4
In their new book, Daniel Kahneman, Olivier Sibony and Cass Sunstein offer strategies for improvement
In the conflict between intuitive and rational decision-making, which side wins?
The father of behavioural economics considers the feeble human brain